Editorial · 30 Nov 2024
Review articlePublished 2013
Recent Developments in Prostate Cancer Screening Guidelines
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Screening recommendations must take into consideration the variable course of PCa for individual patients. While prostate cancer is commonly referred to as a slow growing process, this over-generalization is filled with potentially dangerous assumptions for individuals who harbor aggressive forms of disease. Widespread screening with prostate specific antigen began in the late 1980’s, with mortality due to prostate cancer in decline for the past two decades. This approach has led to a substantial decrease in the diagnosis of high-grade disease. Therefore, population-wide data supports the utility of prostate cancer screening with prostate specific antigen. The purpose of this article is to evaluate the current status of prostate screening in light of the US Preventative Service Task Force guidelines against routine screening and the more recently published American Urological Association guidelines for shared decision-making centered on patient education and autonomy. The difference in recommendations arises from the interpretation of the results from large, randomized prospective screening trials. While the studies may not illustrate a significant benefit for screening, they have notable limitations that make definitive conclusions based on their results, difficult to arrive. Epidemiologic data supports the use of screening modalities for diseases with high prevalence and a prolonged asymptomatic phase. As with any test, there are risks associated with prostate specific antigen screening. The major concerns are over diagnosis and over treatment. While the scientific community works toward more specific screening tests, it is imperative that individual patients are educated and involved in the shared decision-making. Patient perception of their individual harm and benefit becomes a major contributor to the decision-making process when evidence is largely inconclusive and unable to provide definitive direction for the practitioner.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 3 Aug 2015
Using USA guidelines and standards of breast cancer care in an academic medical center: screening to survivorship
Conference abstract · 24 Apr 2017
Lung cancer screening indications and consensus guidelines
Conference abstract · 15 Sep 2014
Cervical cancer: An update on the guidelines for screening and diagnosis of precursor lesions
Editorial · 1 Dec 2025
Prostate Cancer Screening: Beyond PSA, Toward Precision
More from this journal
The newest in Cancer Science & Therapy.
Commentary · 21 Feb 2026
Functional Immune Biomarker Identification in Patients with Breast Cancer
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Ilija Aleksic”
- BylineArticles whose byline prints “Vladamir Mouraviev”
- BylineArticles whose byline prints “David Albala”

